Laura Vidal

2.1k total citations
40 papers, 1.7k citations indexed

About

Laura Vidal is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Laura Vidal has authored 40 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 11 papers in Genetics and 10 papers in Oncology. Recurrent topics in Laura Vidal's work include Virus-based gene therapy research (8 papers), Viral gastroenteritis research and epidemiology (6 papers) and Histone Deacetylase Inhibitors Research (5 papers). Laura Vidal is often cited by papers focused on Virus-based gene therapy research (8 papers), Viral gastroenteritis research and epidemiology (6 papers) and Histone Deacetylase Inhibitors Research (5 papers). Laura Vidal collaborates with scholars based in Spain, United Kingdom and United States. Laura Vidal's co-authors include Johann S. de Bono, Kevin J. Harrington, Alan Melcher, Katie Twigger, Matt Coffey, Hardev Pandha, Richard G. Vile, P. Buhl-Jensen, Poul Knoblauch and Jette Tjørnelund and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Laura Vidal

37 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Laura Vidal Spain 18 1.0k 538 432 217 196 40 1.7k
Giuseppe Roscilli Italy 25 1.1k 1.1× 573 1.1× 272 0.6× 201 0.9× 173 0.9× 48 1.8k
Helen Yu United States 19 1.3k 1.2× 297 0.6× 167 0.4× 268 1.2× 196 1.0× 26 2.0k
Marianne S. Poruchynsky United States 25 1.3k 1.2× 1.3k 2.4× 200 0.5× 344 1.6× 181 0.9× 37 2.5k
Fuminori Teraishi Japan 26 1.1k 1.1× 615 1.1× 495 1.1× 48 0.2× 117 0.6× 80 1.8k
Cristina Balagué Spain 21 1.1k 1.1× 629 1.2× 852 2.0× 92 0.4× 71 0.4× 27 1.7k
Gulietta M. Pupo Australia 24 1.8k 1.8× 935 1.7× 289 0.7× 165 0.8× 134 0.7× 39 2.6k
Chiang J. Li United States 21 1.7k 1.6× 712 1.3× 204 0.5× 122 0.6× 160 0.8× 42 2.8k
Lakshmi Kasturi United States 12 1.3k 1.3× 522 1.0× 169 0.4× 64 0.3× 115 0.6× 14 1.9k
Alain Piché Canada 27 994 1.0× 680 1.3× 190 0.4× 112 0.5× 108 0.6× 57 1.9k
Sharon Bodrug United States 22 2.1k 2.1× 786 1.5× 327 0.8× 352 1.6× 102 0.5× 28 3.2k

Countries citing papers authored by Laura Vidal

Since Specialization
Citations

This map shows the geographic impact of Laura Vidal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Vidal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Vidal more than expected).

Fields of papers citing papers by Laura Vidal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Vidal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Vidal. The network helps show where Laura Vidal may publish in the future.

Co-authorship network of co-authors of Laura Vidal

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Vidal. A scholar is included among the top collaborators of Laura Vidal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Vidal. Laura Vidal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tănase, Alina, Laura Vidal, Martine Poelman, et al.. (2025). The Evolving Landscape in Multiple Myeloma: From Risk Stratification to T Cell-Directed Advanced Therapies. Cancers. 17(3). 525–525.
2.
Quintana, Ángela, Kamal S. Saini, Laura Vidal, et al.. (2024). Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer. ESMO Open. 9(10). 103713–103713. 7 indexed citations
3.
Vidal, Laura, Zodwa Dlamini, Qian Shi, et al.. (2024). Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers. ESMO Open. 9(5). 103373–103373. 7 indexed citations
4.
5.
Vidal, Laura, et al.. (2024). A Novel Minimally Invasive Surgically Induced Skeletal Muscle Injury Model in Sheep. International Journal of Molecular Sciences. 25(11). 5612–5612.
6.
Cantini, Luca, Dario Trapani, Luca Boscolo Bielo, et al.. (2023). Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer. Cancer Treatment Reviews. 123. 102669–102669. 16 indexed citations
7.
Vidal, Laura, Sònia Sentellas, Raquel Horrillo, et al.. (2015). Discovery of 7-azaindole derivatives as potent Orai inhibitors showing efficacy in a preclinical model of asthma. Bioorganic & Medicinal Chemistry Letters. 25(6). 1217–1222. 20 indexed citations
8.
Calbet, Marta, Paul Eastwood, Peter Eichhorn, et al.. (2014). Structure–activity relationships (SAR) and structure–kinetic relationships (SKR) of bicyclic heteroaromatic acetic acids as potent CRTh2 antagonists I. Bioorganic & Medicinal Chemistry Letters. 24(21). 5118–5122. 6 indexed citations
9.
Harrington, Kevin J., Eleni Karapanagiotou, Victoria Roulstone, et al.. (2010). Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers. Clinical Cancer Research. 16(11). 3067–3077. 94 indexed citations
10.
Steele, Nicola, Jane A. Plumb, Laura Vidal, et al.. (2010). Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). Cancer Chemotherapy and Pharmacology. 67(6). 1273–1279. 45 indexed citations
11.
Lassen, Ulrik, L. Rhoda Molife, Laura Vidal, et al.. (2010). A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. British Journal of Cancer. 103(1). 12–17. 72 indexed citations
12.
White, Charles L., Katie Twigger, Laura Vidal, et al.. (2008). Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Therapy. 15(12). 911–920. 124 indexed citations
13.
Steele, Nicola, Jane A. Plumb, Laura Vidal, et al.. (2008). A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors. Clinical Cancer Research. 14(3). 804–810. 211 indexed citations
14.
Vidal, Laura, Hardev Pandha, Timothy A. Yap, et al.. (2008). A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer. Clinical Cancer Research. 14(21). 7127–7137. 184 indexed citations
15.
Vidal, Laura, Alan Melcher, Kate Newbold, et al.. (2007). A Phase I study to evaluate the feasibility, safety and biological effects of intratumoural administration of wild-type Reovirus (REOLYSIN (R)) in combination with radiation in patients with advanced malignancies.. Molecular Cancer Therapeutics. 6. 5 indexed citations
16.
Hingorani, Mohan, Christine L. White, Vijayendra Agrawal, et al.. (2007). Combining Radiation and Cancer Gene Therapy: A Potential Marriage of Physical and Biological Targeting?. Current Cancer Drug Targets. 7(4). 389–409. 16 indexed citations
17.
Greystoke, Alastair, Sarah P. Blagden, Anne Thomas, et al.. (2006). A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours. Annals of Oncology. 17(8). 1313–1319. 19 indexed citations
18.
Vidal, Laura, Jordi Calveras, Pere Clapés, Pau Ferrer, & Glòria Caminal. (2005). Recombinant production of serine hydroxymethyl transferase from Streptococcus thermophilus and its preliminary evaluation as a biocatalyst. Applied Microbiology and Biotechnology. 68(4). 489–497. 29 indexed citations
19.
Vidal, Laura, Sarah P. Blagden, Gerhardt Attard, & Johann S. de Bono. (2005). Making sense of antisense. European Journal of Cancer. 41(18). 2812–2818. 33 indexed citations
20.
Vidal, Laura, et al.. (2003). High‐level production of recombinant His‐tagged rhamnulose 1‐phosphate aldolase in Escherichia coli. Journal of Chemical Technology & Biotechnology. 78(11). 1171–1179. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giuseppe Roscilli Breakdown of academic impact, for papers by Helen Yu Breakdown of academic impact, for papers by Marianne S. Poruchynsky Breakdown of academic impact, for papers by Fuminori Teraishi Breakdown of academic impact, for papers by Cristina Balagué Breakdown of academic impact, for papers by Gulietta M. Pupo Breakdown of academic impact, for papers by Chiang J. Li Breakdown of academic impact, for papers by Lakshmi Kasturi Breakdown of academic impact, for papers by Alain Piché Breakdown of academic impact, for papers by Sharon Bodrug
Rankless by CCL
2026